



## **Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021**

November 11, 2021 at 8:30 AM EST

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Thursday November 18<sup>th</sup>, at 10:00a.m. Eastern Time.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: <http://investors.vcel.com>.

### **About Vericel Corporation**

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI<sup>®</sup> (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel<sup>®</sup> (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid<sup>®</sup>, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company's website at [www.vcel.com](http://www.vcel.com).

Epicel<sup>®</sup> and MACI<sup>®</sup> are registered trademarks of Vericel Corporation. NexoBrid<sup>®</sup> is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

### **Investor Contacts:**

Eric Burns  
ir@vcel.com  
+1 734-418-4411